Chengdu Shuode Pharmaceutical

Chengdu Shuode Pharmaceutical is a wholly-owned subsidiary of Chengdu Easton Biopharmaceuticals (SHSE: 688513), serving as its primary international manufacturing and CDMO platform. Based in Chengdu, China, the company operates state-of-the-art facilities designed to meet NMPA, FDA, and EU GMP standards, specializing in complex formulations such as small-volume injectables, oral solids, and nasal sprays. Shuode focuses on therapeutic areas including anesthesia, analgesia, cardiovascular disease, and oncology, with a growing portfolio of products approved for the U.S. market, such as Methylene Blue and Nicardipine injections. In addition to supporting its parent company's pipeline, Shuode provides comprehensive CDMO services to global pharmaceutical partners, ranging from formulation development to commercial-scale production. The company's strategic focus on high-barrier generics and innovative small molecules positions it as a key player in the internationalization of the Chinese pharmaceutical industry.